|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| A61K 9/19 | |||
| A61K 39/395 | |||
| A61K 9/08 | |||
| A61K 47/26 | |||
| A61K 47/18 |
| (11) | Number of the document | 2648750 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11808178.5 |
| Date of filing the European patent application | 2011-12-08 | |
| (97) | Date of publication of the European application | 2013-10-16 |
| (45) | Date of publication and mention of the grant of the patent | 2017-01-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2011/072248 |
| Date | 2011-12-08 |
| (87) | Number | WO 2012/076670 |
| Date | 2012-06-14 |
| (30) | Number | Date | Country code |
| 421650 P | 2010-12-10 | US |
| (72) |
COSENZA, Marta, CH
HEUSSER, Christoph, CH
NEUGEBAUER, Julia, DE
SCHAADT, Eveline, DE
URLINGER, Stefanie, DE
WOISETSCHLAEGER, Maximilian, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | ANTIBODY FORMULATION |
| ANTIBODY FORMULATION |